Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two ...

Since Xaira’s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. | What has Xaira been doing since its $1 billion raise? Xaira COO Jeff Jonker joins "The Top ...

Intuitive Surgical is recalling one set of its stapler reloads used by its da Vinci robot after incomplete deliveries failed to properly close blood vessels during procedures.  | This comes in the ...

Gilead has handed back a next-gen hepatitis B (HBV) antiviral to Assembly Biosciences, while the two companies continue to partner on other assets. It means Assembly is now back in sole control of ABI ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Renowned cardiologist Eric Topol, M.D., is setting sail with ...